319 related articles for article (PubMed ID: 18210882)
21. Detection of aberrant methylation of four genes in plasma DNA for the detection of breast cancer.
Hoque MO; Feng Q; Toure P; Dem A; Critchlow CW; Hawes SE; Wood T; Jeronimo C; Rosenbaum E; Stern J; Yu M; Trink B; Kiviat NB; Sidransky D
J Clin Oncol; 2006 Sep; 24(26):4262-9. PubMed ID: 16908936
[TBL] [Abstract][Full Text] [Related]
22. Quantitation of promoter methylation of multiple genes in urine DNA and bladder cancer detection.
Hoque MO; Begum S; Topaloglu O; Chatterjee A; Rosenbaum E; Van Criekinge W; Westra WH; Schoenberg M; Zahurak M; Goodman SN; Sidransky D
J Natl Cancer Inst; 2006 Jul; 98(14):996-1004. PubMed ID: 16849682
[TBL] [Abstract][Full Text] [Related]
23. Promoter hypermethylation of RASSF1A and RUNX3 genes as an independent prognostic prediction marker in surgically resected non-small cell lung cancers.
Yanagawa N; Tamura G; Oizumi H; Kanauchi N; Endoh M; Sadahiro M; Motoyama T
Lung Cancer; 2007 Oct; 58(1):131-8. PubMed ID: 17606310
[TBL] [Abstract][Full Text] [Related]
24. Clinical application of methylation specific-polymerase chain reaction in serum of patients with gastric cancer.
Ikoma H; Ichikawa D; Daito I; Nobuyuki T; Koike H; Okamoto K; Ochiai T; Ueda Y; Yamagishi H; Otsuji E
Hepatogastroenterology; 2007; 54(75):946-50. PubMed ID: 17591100
[TBL] [Abstract][Full Text] [Related]
25. Prognostic DNA methylation marker in serum of cancer patients.
Müller HM; Fiegl H; Widschwendter A; Widschwendter M
Ann N Y Acad Sci; 2004 Jun; 1022():44-9. PubMed ID: 15251938
[TBL] [Abstract][Full Text] [Related]
26. Epigenetic changes in tumor suppressor genes, P15, P16, APC-3 and E-cadherin in body fluid.
Chen ML; Chang JH; Yeh KT; Chang YS; Chang JG
Kaohsiung J Med Sci; 2007 Oct; 23(10):498-503. PubMed ID: 18055295
[TBL] [Abstract][Full Text] [Related]
27. [CpG island methylation of E-cadherin gene promoter in gastric carcinoma].
Zhou YN; Xu CP; Han B; Ji R
Ai Zheng; 2005 Oct; 24(10):1220-4. PubMed ID: 16219136
[TBL] [Abstract][Full Text] [Related]
28. DNA methylation in serum of breast cancer patients: an independent prognostic marker.
Müller HM; Widschwendter A; Fiegl H; Ivarsson L; Goebel G; Perkmann E; Marth C; Widschwendter M
Cancer Res; 2003 Nov; 63(22):7641-5. PubMed ID: 14633683
[TBL] [Abstract][Full Text] [Related]
29. Promoter hypermethylation profile of ovarian epithelial neoplasms.
Makarla PB; Saboorian MH; Ashfaq R; Toyooka KO; Toyooka S; Minna JD; Gazdar AF; Schorge JO
Clin Cancer Res; 2005 Aug; 11(15):5365-9. PubMed ID: 16061849
[TBL] [Abstract][Full Text] [Related]
30. Promoter hypermethylation of the SFRP2 gene is a high-frequent alteration and tumor-specific epigenetic marker in human breast cancer.
Veeck J; Noetzel E; Bektas N; Jost E; Hartmann A; Knüchel R; Dahl E
Mol Cancer; 2008 Nov; 7():83. PubMed ID: 18990230
[TBL] [Abstract][Full Text] [Related]
31. Promoter hypermethylation of p16INK4A, p14ARF, CyclinD2 and Slit2 in serum and tumor DNA from breast cancer patients.
Sharma G; Mirza S; Prasad CP; Srivastava A; Gupta SD; Ralhan R
Life Sci; 2007 Apr; 80(20):1873-81. PubMed ID: 17383681
[TBL] [Abstract][Full Text] [Related]
32. Adenomatous polyposis coli gene promoter hypermethylation in non-small cell lung cancer is associated with survival.
Brabender J; Usadel H; Danenberg KD; Metzger R; Schneider PM; Lord RV; Wickramasinghe K; Lum CE; Park J; Salonga D; Singer J; Sidransky D; Hölscher AH; Meltzer SJ; Danenberg PV
Oncogene; 2001 Jun; 20(27):3528-32. PubMed ID: 11429699
[TBL] [Abstract][Full Text] [Related]
33. Quantitative methylation profiling in tumor and matched morphologically normal tissues from breast cancer patients.
Van der Auwera I; Bovie C; Svensson C; Trinh XB; Limame R; van Dam P; van Laere SJ; van Marck EA; Dirix LY; Vermeulen PB
BMC Cancer; 2010 Mar; 10():97. PubMed ID: 20226036
[TBL] [Abstract][Full Text] [Related]
34. Detection of aberrant promoter methylation of GSTP1, RASSF1A, and RARβ2 in serum DNA of patients with breast cancer by a newly established one-step methylation-specific PCR assay.
Yamamoto N; Nakayama T; Kajita M; Miyake T; Iwamoto T; Kim SJ; Sakai A; Ishihara H; Tamaki Y; Noguchi S
Breast Cancer Res Treat; 2012 Feb; 132(1):165-73. PubMed ID: 21594664
[TBL] [Abstract][Full Text] [Related]
35. CpG hypermethylation of promoter region and inactivation of E-cadherin gene in human bladder cancer.
Ribeiro-Filho LA; Franks J; Sasaki M; Shiina H; Li LC; Nojima D; Arap S; Carroll P; Enokida H; Nakagawa M; Yonezawa S; Dahiya R
Mol Carcinog; 2002 Aug; 34(4):187-98. PubMed ID: 12203370
[TBL] [Abstract][Full Text] [Related]
36. Aberrant promoter hypermethylation in serum DNA from patients with silicosis.
Umemura S; Fujimoto N; Hiraki A; Gemba K; Takigawa N; Fujiwara K; Fujii M; Umemura H; Satoh M; Tabata M; Ueoka H; Kiura K; Kishimoto T; Tanimoto M
Carcinogenesis; 2008 Sep; 29(9):1845-9. PubMed ID: 18632757
[TBL] [Abstract][Full Text] [Related]
37. Wnt signalling in human breast cancer: expression of the putative Wnt inhibitor Dickkopf-3 (DKK3) is frequently suppressed by promoter hypermethylation in mammary tumours.
Veeck J; Bektas N; Hartmann A; Kristiansen G; Heindrichs U; Knüchel R; Dahl E
Breast Cancer Res; 2008; 10(5):R82. PubMed ID: 18826564
[TBL] [Abstract][Full Text] [Related]
38. Promoter hypermethylation profile of kidney cancer.
Dulaimi E; Ibanez de Caceres I; Uzzo RG; Al-Saleem T; Greenberg RE; Polascik TJ; Babb JS; Grizzle WE; Cairns P
Clin Cancer Res; 2004 Jun; 10(12 Pt 1):3972-9. PubMed ID: 15217927
[TBL] [Abstract][Full Text] [Related]
39. Aberrant methylation of the THRB gene in tissue and plasma of breast cancer patients.
Ling Y; Xu X; Hao J; Ling X; Du X; Liu X; Zhao X
Cancer Genet Cytogenet; 2010 Jan; 196(2):140-5. PubMed ID: 20082849
[TBL] [Abstract][Full Text] [Related]
40. Tumor-derived aberrant methylation in plasma of invasive ductal breast cancer patients: clinical implications.
Hu XC; Wong IH; Chow LW
Oncol Rep; 2003; 10(6):1811-5. PubMed ID: 14534701
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
